Repurposing of known drugs to newer clinical conditions is a promising avenue for finding novel therapeutic applications for tuberculosis.
INTRODUCTION
Tuberculosis is the world leading infectious killer disease accounting for 1.3 million deaths and an additional 374 000 deaths among HIV-positive people globally in 2016 (WHO 2017) . Though tuberculosis can be cured using the currently available drugs, emergence of drug resistant Mycobacterium tuberculosis that results in multiple forms drug resistant TB including multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) necessitates the discovery of newer therapeutics for the sustained success in the treatment and control of TB. Another difficulty in the management of TB is that minimum of six months is required for the treatment with rifampin, isoniazid, ethambutol and pyrazinamide for first four months and rifampin and isoniazid for next two months. The present situation of the TB treatment certainly demands for much more effective drugs with which we can treat the TB in significantly shorter time and lesser doses.
Conventional process of drug discovery needs about 10 years or more and a big budget of up to billion dollars. In this background, identification of newer therapeutic uses for already known drugs against other diseases, which is referred as repurposing is considered to be a promising avenue in the pharmaceutical industry and academia (Ashburn and Thor 2004) . Repurposing is also known by several other terminologies viz., redirecting, repositioning, or reprofiling while identifying new clinical use for molecules which failed during the clinical development stage for its original goal is referred as drug rescue (Langedijk et al., 2015) . The scientific principle of repurposing of drugs is that some of the drugs can interact with multiple drug targets. Polypharmacology is a term used to explain the ability of those drugs which can act simultaneously and specifically on multiple targets (Anighoro et al., 2014) . Drugs with polypharmacological nature have relatively lower chances for the development of drug resistance since they target multiple drug targets, and show better efficacy compared to drugs with specificity for a single target, especially against advanced-stage diseases (Anighoro et al., 2014; Peters, 2013) . However, the polypharmacology differs from the unintended promiscuousity of drugs with unknown target that leads to adverse reactions (Anighoro et al., 2014) .
Several drugs have already been successfully repurposed for new diseases, outside the original medical scope. For example, metformin is a commonly used drug for the treatment of type 2 diabetes, now repurposed for cancer (Kasznicki et al., 2014) , colesevelam, used for hyperlipidemia and repurposed for type-2-diabetes (Finsterer and Frank, 2013) can also be repurposed for the treatment of other diseases; for example, zidovudine was first synthesized as a potential anti-cancer agent in 1964 but failed in the cancer treatment, and later in 1984 it was discovered to be active against HIV, and subsequently approved for the treatment in 1987 (Broder, 2010) . Recognizing the potential of repurposing of drugs in discovery of newer therapeutic applications especially against diseases that has no drugs to treat or difficult treat, recently government agencies viz., National Institute of Health (USA) and Medical Research Council (UK) established collaborative research with private pharmaceutical industries to promote the repurposing of drugs (Frail et al., 2015) .
Several drugs, including, fluroquinolones, clofazimine, meropenem and clavulanate were primarily used for other clinical conditions and now repurposed successfully for treatment of drug resistant forms of TB (Palomino and Martin 2013; Maitra et al., 2015) . In addition, several more drugs, to name a few, verapamil (Adams et al., 2011 , Gupta et al., 2013 and Adams et al., 2014 , statins, (Skerry et al., 2014 , Parihar et al., 2014 and Lobato et al., 2014 and metformin (Singhal et al., 2014) have been reported to have potential use in the treatment of TB. These evidences suggest that repurposing of old drugs could be a promising avenue for finding a newer therapeutic drugs for TB.
The genome of M. tuberculosis encodes for about 4000 proteins which necessitates scrupulous selection of drug targets for drug discovery. Anthranilate phosphoribosyltransferase (trpD, Rv2192c) is known to be essential for the optimal growth of M. tuberculosis ; it was also demonstrated that the M. tuberculosis auxotrophic for tryptophan (Smith et al., 2001) Ref:http://www.uniprot.org/uniprot/P9WPA7) and it is an essential gene for the optimal growth of M. tuberculosis Awasthy et al., 2010) and survival during infection . Further, several bioinformatics analysis revealed trpD (Defelipe et al., 2016; Kushwaha and Shakya 2010; Anishetty et al., 2005) and coaA (Raman et al., 2008; Defelipe et al., 2016) as potential drug targets for M. tuberculosis. Both trpD and coaA of M. tuberculosis lack homolog proteins in the human genome. For both of these two proteins, three dimensional structures are available in the Protein Data Bank (Castell et al., 2013 and Chetnani et al., 2010) . All these factors encouraged us to select trpD and coaA as target proteins against which molecular docking was performed.
In the present study we undertook an effort to prioritize 1554 FDA approved drugs using docking-based virtual screening against two of the potential drug targets and tested some of the prioritized drugs using Luciferase Reporter Phage (LRP) assay against M.
tuberculosis. We identified cefpodoxime and lymecycline to inhibit drug susceptible and resistant strains of M. tuberculosis, and have synergistic role with two of the major antitubercular drugs, rifampin and isoniazid.
METHODS

In silico prioritization of drugs
A total of 1554 FDA-approved drugs were obtained from DrugBank and virtually screened against two proteins namely anthranilate phosphoribosyltransferase (trpD -Rv2192c) and pantothenate kinase (coaA -Rv1092c) of M. tuberculosis using molecular docking with the help of two different docking tools, namely Glide and AutoDock Vina.
Rigid body docking algorithm was employed for initial screening. Those drugs which were ranked in top 10% during rigid-body docking by both Glide and ADV were subjected for induced-fit docking algorithm for further prioritization. Figure 1 and 4 display the workflow of the procedure.
In vitro testing by LRP assay against M. tuberculosis
Biological activity of five of the prioritized drugs, namely, cefpodoxime, montelukast, lymecycline, diosmin and carboprost tromethamine were evaluated against M. tuberculosis using LRP assay Dusthackeer et al., 2008; Manikkam et al., 2014) .
Initially, all of the drugs were tested against drug sensitive M. tuberculosis H37Rv strain at two different concentrations (20 µg/ml and 100µg/ml). Those drugs which were active in the initial screening were further tested against multidrug-resistant strains of M. tuberculosis at four different concentrations (10, 20, 50 and 100µg/ml). Additionally, the active drugs were also tested for synergistic effect with two of the major first-line anti-tubercular drugs rifampin and isoniazid using LRP assay.
RESULTS
Prioritized drugs against trpD
We found a total of 26 drugs to be ranked consistently at the end of rigid docking of 1554 FDA approved drugs against trpD. When we subjected these 26 drugs for induced-fit docking against trpD, 15 drugs were observed to be ranked within top 10 ranks by either Glide or AutoDock Vina (Table 1) . Experimentally studied compound 2,2'-iminodibenzoic acid in complex with trpD (PDB ID: 3QQS) was used as the control molecule and docked along with trpD. All of the 15 prioritized drugs were found to have better binding affinity score by ADV than the control molecule though only top three ranked molecules were observed to have better Glide score than the control molecule (Table 1) . Among these 15
shortlisted drugs, five drugs, namely, acarbose (Glide rank 1 and ADV tank: 2), cefpodoxime
(2, 5), montelukast (6, 6), lymecycline (7, 1) and idarubicin (10, 7) were ranked consistently within the top 10 drugs by both Glide and ADV.
Prioritized drugs against coaA
When 1554 drugs were screened against coaA of M. tuberculosis, we observed 16 drugs to be ranked consistently within top 10% in the rigid docking by both Glide and ADV.
When we subjected these 16 drugs for induced fit docking by both Glide and ADV, 14 drugs were observed within top 10 ranks (Table 2) . Phosphopantothenate (PAZ (N-[(2R)-2hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanine), one of the ligand resolved in complex with coaA (PDB ID: 3AEZ) was used as the control molecule during docking. All of the 14 drugs were observed to have better binding affinity score with coaA than the control molecule, PAZ by ADV while only 8 drugs scored better than PAZ by Glide (Table 2) . A total of six drugs namely, flavin adenine dinucleotide (Glide rank: 3, ADV rank: 3), carboprost tromethamine (4, 6), montelukast (5, 9) , paromomycin (7, 5), calcium gluceptate (8, 10), lymecycline (9, 4) were found to be consistently ranked within top 10 drugs by both Glide and ADV.
Lymecycline and cefpodoxime inhibit both drug susceptible and resistant strains of
M. tuberculosis
Initial in vitro screening for activity was carried out at two different concentrations (10, 20, 50 and 100 g/ml) against drug sensitive strains of M. tuberculosis. We found two drugs namely cefpodoxime and lymecycline to inhibit M. tuberculosis H37Rv. Cefpodoxime inhibited drug sensitive strains of M. tuberculosis at 20, 50 and 100 g/ml concentrations and lymecycline at 10, 20, 50 and 100 g/ml concentrations (Table 3) . Anti-mycobacterial activity against MDR stains of M. tuberculosis was carried out at 20 and 100 g/ml. Both cefpodoxime and lymecycline inhibited MDR strains at 20 and 100 g/ml concentrations.
Other three drugs tested namely, montelukast, diosmin and carboprost tromethamine did not show inhibitory activity against M. tuberculosis.
Lymecycline and cefpodoxime show synergistic activity with rifampin and isoniazid against M. tuberculosis
Synergistic role of cefpodoxime and lymecycline against M. tuberculosis were determined in the presence of rifampicin and isoniazid (Table 3) . Cefpodoxime showed synergistic inhibitory role at 20 g/ml concentration with rifampin (2 g/ml) and isoniazid 
DISCUSSION
The long duration of time needed for the treatment of TB using the currently available drugs and the emergence drug resistant TB demand for better therapeutic drugs for the successful and sustained control of TB. Given the cost and time required for the development of new drugs using conventional discovery process, recent success in the repurposing of drugs has encouraged researchers to pursue research in this discipline, especially for TB.
Since M. tuberculosis encodes for more than 4000 proteins, utmost care should be taken for the selection of target proteins based on which the whole prioritization of drugs is determined. Given the fact that both of the targets selected (trpD and coaA) are essential for the optimal growth or survival of M. tuberculosis Smith et al., 2001; Awasthy et al., 2010; , molecules used to inhibit these proteins are likely to have therapeutic value for tuberculosis.
The Our prioritized drugs becomes significant because a total of 4 of these 29 drugs have already been reported to have activity against M. tuberculosis. Among the 15 drugs prioritized against trpD, two drugs namely acarbose (ranked 1 and 2 by Glide and ADV, respectively) and idarubicin (rank: 10 and 7) were reported previously as active against M.
tuberculosis. For example, acarbose has been reported to inhibit trehalose synthase (treS) of
Mycobacterium smegmatis which share 83% sequence identity with treS of M. tuberculosis (Caner et al., 2013; and Pan et al., 2008) . Idarubicin is already known to target bacterial primase dnaG, a DNA-dependent RNA polymerase and inhibit M. smegmatis (MIC = 0.6 μM) and M. tuberculosis (MIC = 80 μM) (Gajadeera et al 2015) . Similarly, two of the 14 prioritized drugs against coaA, namely paromomycin (rank:7 and 5) and daunorubicin (rank: 2 and 14) were previously reported to have antimycobacterial activity. Particularly, paromomycin was demonstrated to have early bactericidal activity against M. tuberculosis (Donald et al., 2000) in a pilot clinical research study in newly diagnosed pulmonary tuberculosis patients (Donald et al., 2000) . Daunorubicin was recently demonstrated to inhibit growth of M. tuberulosis and M. smegmatis under in vitro conditions (Gajadeera et al., 2015) .
Since four of 29 prioritized drugs (acarbose, idarubicin, paromomycin and daunorubicin)
have already reported to have potential use for the treatment of TB, especially evidence generated from clinical research for paromomycin (Donald et al., 2000) encourage us to speculate that other drugs prioritized using the same method are likely to have potential activity against M. tuberculosis.
Conclusion
Since 4 out of 25 prioritized drugs are already reported to have potential use against M. tuberculosis using in vitro studies and clinical research, the procedure employed in this study becomes significant, thus, it can be adopted to prioritize drugs for repurposing against any other diseases. Biological activity of lymecycline and cefpodoxime against drug sensitive and drug resistant strains of M. tuberculosis and their synergistic role with rifampin and isoniazid suggest that these two drugs have potential for repurposed in the treatment of TB. Fig 3A shows the trpD in solid ribbon form (grey in color) while cefpodoxime is showed in red stick form with the active site of the protein is highlighted as yellow surface. Fig 3B shows the effective fitting of the cefpodoxime in the active site of the trpD (yellow surface) and cefpodoxime in stick form. Fig 3C shows the interacting amino acids of trpD (cyan color) by hydrogen bonds (pink color dotted lines) with the cefpodoxime (red color, stick form). Fig 3D displays the inter-molecular interactions between the trpD and cefpodoxime in two dimensional view. Fig 5A shows the coaA in solid ribbon form (grey in color) while lymecycline is showed in red stick form with the active site of the protein is highlighted as yellow surface. Fig 5B shows the effective fitting of the lymecycline in the active site of the coaA (yellow surface). Fig 5C shows the interacting amino acids of coaA (cyan color) by hydrogen bonds (pink color dotted lines) with the lymecycline (red color, stick form). Fig 5D displays the inter-molecular interactions between the coaA and cefpodoxime in two dimensional view. Note: Percent of reduction in relative light unit (RLU) is given within brackets.
